Summary:
A systematic review finds that women with polyendocrine metabolic ovarian syndrome (PMOS), historically known as polycystic ovary syndrome (PCOS), show increased vulnerability to subtle cognitive problems—most notably impairments in memory and executive function—and may be at higher long-term risk for neurodegenerative decline. The evidence indicates that this elevated risk for Alzheimer’s disease and other dementias is largely driven by shared metabolic conditions, especially chronic insulin resistance and obesity, rather than by PMOS acting alone.
Key Facts:
- Prevalence and cognitive impact: PMOS affects an estimated 10%–15% of women worldwide. Clinical studies repeatedly report mild but consistent deficits in executive functioning, working memory, and cognitive flexibility, along with measurable changes in brain structure and connectivity.
- Metabolic pathway to dementia: The apparent link between PMOS and Alzheimer’s disease appears to be mediated primarily through metabolic comorbidities—insulin resistance, obesity, chronic inflammation—rather than PMOS acting as an independent neurodegenerative trigger.
- Treatment implications: Because systemic metabolic dysfunction connects ovarian endocrine disease to brain health, strategies that target metabolic syndrome and obesity may offer dual benefits for reproductive, cardiovascular, and long-term cognitive health.
Source: Endocrine Society / University of Alabama at Birmingham
Overview: Affecting roughly one in ten to one in seven women worldwide, polyendocrine metabolic ovarian syndrome (PMOS), previously referred to as PCOS, is well known for its reproductive and metabolic consequences—infertility, increased endometrial cancer risk, type 2 diabetes, cardiovascular disease, and stroke. Newer research shows its influence may extend into the brain, with implications for cognitive aging and dementia risk.
An international team published a comprehensive review in the Journal of the Endocrine Society that examined how PMOS intersects with neurodegenerative biology. Their synthesis of clinical and mechanistic studies concluded that women with PMOS demonstrate cognitive and brain changes that could predispose them to later-life dementia, but that these effects are largely explained by coexisting metabolic dysfunction.
Cognitive Changes and Brain Alterations
Although PMOS has been primarily characterized as an ovarian and metabolic disorder, it frequently coexists with neuropsychiatric symptoms such as anxiety and depression and shows measurable cognitive impacts. Across published studies reviewed through October 2025, researchers identified a reproducible pattern: women with PMOS scored lower on tests of executive function, working memory, and cognitive flexibility. Neuroimaging studies also report structural and functional differences—hippocampal and white matter changes and altered network connectivity—that align with these cognitive findings.
The authors emphasize that these neurocognitive findings do not prove PMOS independently causes neurodegeneration. Instead, the data indicate a pathway in which metabolic comorbidities common to PMOS amplify long-term brain vulnerability.
“Clinically, PMOS patients exhibit mild but reproducible impairments in executive function and memory, alongside structural and functional brain alterations, which could suggest greater risk for Alzheimer’s disease and dementia,” said co-author Ricardo Azziz, MD, MPH, MBA, of the University of Alabama at Birmingham. “Current evidence suggests that any association between PMOS and Alzheimer’s disease and dementia is likely mediated by metabolic comorbidities, particularly insulin resistance and obesity, rather than an independent effect of PMOS itself.”
The Insulin Resistance Bridge
The review highlights insulin resistance as a central mechanistic link. In PMOS, peripheral tissues often become less responsive to insulin, prompting chronic hyperinsulinemia. Over time, this metabolic stress and chronic low-grade inflammation can impair glucose transport into the brain. Reduced metabolic support, especially in energy-demanding regions such as the hippocampus and frontal cortex, can promote synaptic dysfunction and processes implicated in Alzheimer’s disease, including tau phosphorylation and amyloid-beta accumulation.
Because obesity and metabolic syndrome frequently accompany PMOS, these overlapping conditions amplify metabolic stress and inflammation, increasing long-term susceptibility to neurodegenerative changes.
Knowledge Gaps and Next Steps
The authors note key limitations in the existing literature. Longitudinal cohort studies that track dementia incidence in women with PMOS across decades are still scarce. PMOS is heterogeneous in its hormonal and metabolic presentations, so identifying which specific profiles convey the highest cognitive risk remains a priority. Likewise, clinical trials testing whether PMOS-specific or metabolic-targeted interventions reduce cognitive decline are lacking.
“Understanding how these two disorders that significantly impact women’s health worldwide are inter-related presents the opportunity to not only understand what these two very important morbidities have in common but also to discover new pathways and causes which could guide the development of novel treatments for these devastating diseases,” Azziz added.
Practical implications from the review suggest clinicians should emphasize early metabolic management—weight control, insulin-sensitizing strategies, and cardiovascular risk reduction—not only for reproductive and cardiometabolic benefits but also as a potential long-term defense against cognitive decline and dementia.
Funding: The study was funded by the Foundation for Research and Education Excellence.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full for this summary.
- Additional context was added by editorial staff for clarity.
About this dementia Research:
- Media Contact: Colleen Williams
- Source: Endocrine Society
- Image Credit: Image credited to Neuroscience News
- Original Research (Open Access): Journal of the Endocrine Society (Oct 1, 2026). Title: “Potential links between PCOS/PMOS and Alzheimer disease and related dementias.” Authors: Mina Amiri, Armita Kakavand Hamidi, Daniel L. Farkas, Richard P. Buyalos, and Ricardo Azziz.
- DOI: 10.1210/jendso/bvag206
Abstract
Potential links between PCOS/PMOS and Alzheimer disease and related dementias
Background
Polycystic ovary syndrome / polyendocrine metabolic ovarian syndrome (PCOS/PMOS) is a common endocrine disorder with substantial reproductive and metabolic consequences. Researchers are increasingly exploring whether the disorder’s metabolic and inflammatory features could contribute to later-life neurological decline, including cognitive impairment and Alzheimer’s disease, via shared biological pathways.
Methods
The authors performed a comprehensive PubMed search through October 2025, selecting studies that examined cognitive performance, brain imaging, neurodegenerative biomarkers, and dementia risk in PCOS/PMOS populations.
Results
The review identified multiple plausible mechanisms linking PCOS/PMOS to Alzheimer’s-relevant biology: insulin resistance, chronic inflammation, hormonal imbalance, and cardiovascular dysfunction. These processes can converge on neurodegenerative pathways—impaired amyloid clearance, tau hyperphosphorylation, oxidative stress, and cerebral metabolic deficits. Clinically, patients with PCOS/PMOS show mild but consistent impairments in executive function and memory and measurable brain changes. However, many findings are influenced by coexisting metabolic dysfunction, and direct epidemiological evidence for higher dementia incidence in PCOS/PMOS is limited and inconsistent.
Conclusion
Current evidence suggests that any relationship between PCOS/PMOS and Alzheimer’s disease is most likely mediated by metabolic comorbidities—particularly insulin resistance and obesity—rather than being a direct effect of PCOS/PMOS itself. Clinical practice should focus on optimizing metabolic health in affected women, while future longitudinal and interventional studies are needed to clarify long-term neurological outcomes and whether targeted treatments can reduce cognitive risk.